NCT05489393 is a clinical trial in DRPLA, sponsored by CureDRPLA.

Who is sponsoring NCT05489393?

NCT05489393 is sponsored by CureDRPLA.

Is NCT05489393 still recruiting?

NCT05489393 is currently recruiting now. Last updated 17 March 2026.

Last reviewed 2026-03-17 · How we verify

NCT05489393

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CureDRPLA Global Patient Registry

Recruiting now Last updated 17 March 2026

What this trial tests

trial in DRPLA in 100 participants. Currently enrolling.

Timeline

1 March 2021

Primary endpoint
1 November 2031

1 November 2031

Quick facts

Lead sponsor	CureDRPLA
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 March 2021
Primary completion	1 November 2031
Estimated completion	1 November 2031
Sites	1 location across United States

Conditions studied

DRPLA — all drugs for DRPLA →

Sponsor

CureDRPLA

Who can join

Adults 0 to 100, any sex, with DRPLA. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the CureDRPLA Global Patient Registry is to establish a longitudinal database of patient-reported data on individuals affected with Dentatorubral-pallidoluysian atrophy (DRPLA) from anywhere in the world. The CureDRPLA Global Patient Registry will address patient needs by: * Expanding patient engagement by documenting quality of life outcomes. * Providing anonymized data to the DRPLA research community on patient experience with the disease and priorities for treatment. * Connecting DRPLA patients with opportunities to participate in clinical research.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.
Tenchov R, Sasso JM, Zhou QA. · · 2024 · cited 31× · PMID 38996083 · DOI 10.1021/acschemneuro.4c00184
Establishing resources and increasing awareness to advance research on Dentatorubral-pallidoluysian atrophy toward a treatment: a patient organization perspective.
Prades S, Compton A, Carroll JB. · · 2024 · PMID 38716233 · DOI 10.1177/26330040241249189

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05489393 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CureDRPLA
Last refreshed: 17 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05489393.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing